65,437 trials
Head and Neck Neoplasms · Carcinoma, Squamous Cell
Primary: Tumor Shrinkage Before Crossover (Stage 1) of the Trial as Per Investigator Assessment — -3.86; -2.37 millimeter — p=0.7606
Spondyloarthropathies
Primary: Assessment in Axial Spondyloarthritis International Society 20 % (ASAS20) Response Criteria at Week 12 — 38.3; 57.7; 63.6; 60.6 percentage of participants — p==0.004
Prostate Cancer · Adenocarcinoma of the Prostate
Primary: Endorectal MRI Response After Completion of 6 Cycles of Neoadjuvant Therapy — 0.29 proportion of participants
Hypertension, Pulmonary · Ventricular Dysfunction, Left
Primary: Pulmonary Artery Mean Pressure (PAPmean) at Rest - Change From Baseline to Week 16 — -6.1; -0.8; -4.5; -4.0 mmHg — p=0.1044
Pulmonary Disease, Chronic Obstructive
Primary: Time-adjusted Area Under the Curve (AUC) (i.e., Weighted Mean) for 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at the End of Each 28-day Treatment…
Cardiac Edema
Primary: Body Weight — -1.68; -2.14 Kg
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival — 6.9 Months
Overactive Bladder
Primary: Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12. — -2.85; -2.22; -3.12 Episodes per 24 hours — p=<0.0001
Epilepsy
Primary: Acute SAE Rate — 6.2 percentage of participants
Parkinson's Disease
Primary: Correlation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex. — 0.5869 unitless
Actinic Keratosis
Primary: Complete Clearance Rate — 14; 7; 13; 8 participants — p=0.0041
Hematologic Malignancy · Myelodysplastic Syndrome (MDS) · Aplastic Anemia
Primary: The Number of Participants Reaching Primary Endpoint of Absolute Neutrophil Count (ANC) of 500/uL (Engraftment). — 3 participants
Angioedema
Primary: Time to Onset of Symptom Relief (TOSR) — 2.5; 4.6 Hours — p=0.142
Vaginitis · Infectious Vaginosis
Primary: Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment — 67.1; 79.2; 32.9; 20.8 Percentage of Participants
Venous Thromboembolism
Primary: Presence of Deep Vein Thrombosis (DVT) or Pulmonary Embolus (PE) — 2; 2; 1; NA participants